cp wire

CP Wire Articles

Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer
  • Imfinzi is currently approved in the US for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and... read more
Tue, 09/25/18 - 09:51 am
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
  • Alunbrig achieved a 51% increase in progression free survival compared to crizotinib
  • Alunbrig received Breakthrough Therapy Designation from the FDA for the treatment of patients... read more
Tue, 09/25/18 - 09:33 am
Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Huge Oral Mucositis Market
  • Oral mucositis is potentially a 1 billion dollar market
  • Additional expenses incurred by patients suffering from SOM are estimated to be as high as $18,000 to $25,000 per case in the... read more
Mon, 09/24/18 - 10:13 am
Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes

AstraZeneca on 9/24/18 announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT-2 inhibitor CVOT... read more

Mon, 09/24/18 - 09:36 am
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C


Gilead Sciences, Inc. (NASDAQ: GILD) announced on 9/24/18 plans to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir... read more

Mon, 09/24/18 - 09:22 am

Pages